<CTGovProtocol id="CDR0000363918">
  <RequiredHeader>
    <DownloadDate>Information obtained from ClinicalTrials.gov on 2005-12-09</DownloadDate>
    <LinkText xref="http://clinicaltrials.gov/show/NCT00080028">Link to the current ClinicalTrials.gov record.</LinkText>
  </RequiredHeader>
  <IDInfo>
    <OrgStudyID>PCYC-0210</OrgStudyID>
    <NCTID>NCT00080028</NCTID>
  </IDInfo>
  <BriefTitle>Motexafin Gadolinium With Chemotherapy and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer</BriefTitle>
  <OfficialTitle>Phase I Trial of Motexafin Gadolinium and Chemoradiation in Locally Advanced, Squamous Cell Carcinoma of the Head and Neck</OfficialTitle>
  <Sponsors>
    <PDQSponsorship>Pharmaceutical/Industry</PDQSponsorship>
    <LeadSponsor ref="CDR0000029624">Pharmacyclics, Inc.</LeadSponsor>
  </Sponsors>
  <BriefSummary>
    <Para>The purpose of this study is to evaluate the safety of adding the investigational drug Motexafin Gadolinium to the standard treatment of radiation therapy and chemotherapy with drugs called 5-FU and cisplatin in patients with advanced head and neck cancer.</Para>
</BriefSummary>
  <CTEntryCriteria>
    <Para>Inclusion Criteria:</Para>
    <ItemizedList Style="bullet">
      <ListItem>At least 18 years of age</ListItem>
    </ItemizedList>
    <ItemizedList Style="bullet">
      <ListItem>Each patient must sign a study-specific informed consent form</ListItem>
    </ItemizedList>
    <ItemizedList Style="bullet">
      <ListItem>Newly diagnosed, locally advanced, non-metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) arising from a primary site in the oropharynx, hypopharynx, or larynx confirmed by evaluation of fine needle aspiration or biopsy samples and MRI</ListItem>
    </ItemizedList>
    <ItemizedList Style="bullet">
      <ListItem>Eligible for curative intent treatment with hyperfractionated radiation and concurrent 5-FU and cisplatin</ListItem>
    </ItemizedList>
    <ItemizedList Style="bullet">
      <ListItem>Karnofsky Performance Status score of at least 60%</ListItem>
    </ItemizedList>
    <ItemizedList Style="bullet">
      <ListItem>Primary tumor at least 4 cm in diameter</ListItem>
    </ItemizedList>
    <Para>Exclusion Criteria:</Para>
    <Para>Laboratory Values of:</Para>
    <ItemizedList Style="bullet">
      <ListItem>Serum creatinine &gt; 1.8 mg/dL; unless 24-hour urine creatinine clearance is â‰¥ 70 mL/min</ListItem>
    </ItemizedList>
    <ItemizedList Style="bullet">
      <ListItem>Serum total bilirubin &gt; 1.5 times the upper limit of normal</ListItem>
    </ItemizedList>
    <ItemizedList Style="bullet">
      <ListItem>ALT (formerly SGPT) &gt; 1.5 times the upper limit of normal</ListItem>
    </ItemizedList>
    <ItemizedList Style="bullet">
      <ListItem>Alkaline phosphatase &gt; 1.5 times the upper limit of normal</ListItem>
    </ItemizedList>
    <ItemizedList Style="bullet">
      <ListItem>Absolute neutrophil count (ANC) &lt; 1500/L</ListItem>
    </ItemizedList>
    <ItemizedList Style="bullet">
      <ListItem>Platelet count &lt; 100,000/L</ListItem>
    </ItemizedList>
    <ItemizedList Style="bullet">
      <ListItem>3+ or greater proteinuria on urinalysis</ListItem>
    </ItemizedList>
    <Para>and</Para>
    <ItemizedList Style="bullet">
      <ListItem>Squamous Cell Carcinoma of the Head and Neck arising from a primary site in the oral cavity or nasopharynx</ListItem>
    </ItemizedList>
    <ItemizedList Style="bullet">
      <ListItem>Distant metastases</ListItem>
    </ItemizedList>
    <ItemizedList Style="bullet">
      <ListItem>Prior history of cancer at any site treated with radiotherapy and/or chemotherapy</ListItem>
    </ItemizedList>
    <ItemizedList Style="bullet">
      <ListItem>History of SCCHN diagnosed within 5 years of current diagnosis</ListItem>
    </ItemizedList>
  </CTEntryCriteria>
  <CTGovDisclaimer>Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain 
the same text. Minor
changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and
contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should
be directed to ClinicalTrials.gov.</CTGovDisclaimer>
  <CurrentProtocolStatus>Closed</CurrentProtocolStatus>
  <ProtocolPhase>Phase I</ProtocolPhase>
  <ProtocolDetail>
    <StudyType>Clinical trial</StudyType>
    <StudyCategory>
      <StudyCategoryName>Treatment</StudyCategoryName>
      <Intervention>
        <InterventionType ref="CDR0000039000">radiosensitization</InterventionType>
        <InterventionNameLink ref="CDR0000042391">motexafin gadolinium</InterventionNameLink>
      </Intervention>
      <Intervention>
        <InterventionType ref="CDR0000038999">chemosensitization/potentiation</InterventionType>
        <InterventionNameLink ref="CDR0000042391">motexafin gadolinium</InterventionNameLink>
      </Intervention>
      <Intervention>
        <InterventionType ref="CDR0000038085">radiation therapy</InterventionType>
      </Intervention>
      <Intervention>
        <InterventionType ref="CDR0000039455">chemotherapy</InterventionType>
        <InterventionNameLink ref="CDR0000043130">fluorouracil</InterventionNameLink>
        <InterventionNameLink ref="CDR0000039515">cisplatin</InterventionNameLink>
      </Intervention>
      <Intervention>
        <InterventionType ref="CDR0000038581">combination therapy</InterventionType>
        <InterventionNameLink ref="CDR0000372885">cisplatin/fluorouracil/motexafin gadolinium</InterventionNameLink>
      </Intervention>
    </StudyCategory>
  </ProtocolDetail>
  <Eligibility>
    <HealthyVolunteers>No</HealthyVolunteers>
    <LowAge>18</LowAge>
    <HighAge>120</HighAge>
    <AgeText>18 and over</AgeText>
    <Diagnosis>
      <SpecificDiagnosis ref="CDR0000040743">stage III squamous cell carcinoma of the hypopharynx</SpecificDiagnosis>
      <DiagnosisParent ref="CDR0000040103">stage III hypopharyngeal cancer</DiagnosisParent>
      <DiagnosisParent ref="CDR0000038955">hypopharyngeal cancer</DiagnosisParent>
      <DiagnosisParent ref="CDR0000038961">head and neck cancer</DiagnosisParent>
      <DiagnosisParent ref="CDR0000043666">body system/site cancer</DiagnosisParent>
      <DiagnosisParent ref="CDR0000041060">cancer</DiagnosisParent>
      <DiagnosisParent ref="CDR0000040460">adult solid tumor</DiagnosisParent>
      <DiagnosisParent ref="CDR0000040461">solid tumor</DiagnosisParent>
      <DiagnosisParent ref="CDR0000040682">hypopharyngeal squamous cell carcinoma</DiagnosisParent>
    </Diagnosis>
    <Diagnosis>
      <SpecificDiagnosis ref="CDR0000040750">stage III squamous cell carcinoma of the larynx</SpecificDiagnosis>
      <DiagnosisParent ref="CDR0000040113">stage III laryngeal cancer</DiagnosisParent>
      <DiagnosisParent ref="CDR0000038962">laryngeal cancer</DiagnosisParent>
      <DiagnosisParent ref="CDR0000038961">head and neck cancer</DiagnosisParent>
      <DiagnosisParent ref="CDR0000043666">body system/site cancer</DiagnosisParent>
      <DiagnosisParent ref="CDR0000041060">cancer</DiagnosisParent>
      <DiagnosisParent ref="CDR0000040460">adult solid tumor</DiagnosisParent>
      <DiagnosisParent ref="CDR0000040461">solid tumor</DiagnosisParent>
      <DiagnosisParent ref="CDR0000040683">laryngeal squamous cell carcinoma</DiagnosisParent>
    </Diagnosis>
    <Diagnosis>
      <SpecificDiagnosis ref="CDR0000040725">stage III squamous cell carcinoma of the oropharynx</SpecificDiagnosis>
      <DiagnosisParent ref="CDR0000040136">stage III oropharyngeal cancer</DiagnosisParent>
      <DiagnosisParent ref="CDR0000038965">oropharyngeal cancer</DiagnosisParent>
      <DiagnosisParent ref="CDR0000038961">head and neck cancer</DiagnosisParent>
      <DiagnosisParent ref="CDR0000043666">body system/site cancer</DiagnosisParent>
      <DiagnosisParent ref="CDR0000041060">cancer</DiagnosisParent>
      <DiagnosisParent ref="CDR0000040460">adult solid tumor</DiagnosisParent>
      <DiagnosisParent ref="CDR0000040461">solid tumor</DiagnosisParent>
      <DiagnosisParent ref="CDR0000040680">oropharyngeal squamous cell carcinoma</DiagnosisParent>
    </Diagnosis>
  </Eligibility>
  <VerificationDate>April 2005</VerificationDate>
  <LastChangedDate>December 8, 2005</LastChangedDate>
</CTGovProtocol>